Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Mirati Therapeutics Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07415031CT.gov A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | — | Recruiting | — | — | — |
NCT07610941CT.gov Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies | — | Recruiting | — | — | — |
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT07158918CT.gov ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06736379CT.gov Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | — | Recruiting | — | — | — |
NCT06932952CT.gov A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06549946CT.gov Ixovex-1 Single Agent and Combination Therapy | — | Recruiting | — | — | — |
NCT06576037CT.gov Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | — | Recruiting | — | — | — |
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT06171178CT.gov A Study of ASP1012 in Adults With Solid Tumors | — | Terminated | — | — | — |
Show 135 more trialsShow fewer
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT06205706CT.gov BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06049212CT.gov Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | — | Active Not Recruiting | — | — | — |
NCT06036836CT.gov Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | — | Completed | — | — | — |
NCT05996445CT.gov A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05859074CT.gov A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | — | Recruiting | — | — | — |
NCT05784688CT.gov Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05491317CT.gov A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05642780CT.gov SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05653882CT.gov A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05514444CT.gov Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) | — | Completed | — | — | — |
NCT05419817CT.gov Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | — | Withdrawn | — | — | — |
NCT05378425CT.gov A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT05273554CT.gov A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05174585CT.gov JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT07016997CT.gov A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT05382559CT.gov A Study of ASP3082 in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05101070CT.gov S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05346484CT.gov A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05176509CT.gov A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors | — | Completed | — | — | — |
NCT05320588CT.gov A Study in Patients With Advanced Cancers | — | Recruiting | — | — | — |
NCT05082610CT.gov A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05064280CT.gov Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | — | Recruiting | — | — | — |
NCT05128487CT.gov A Study of NDI 1150-101 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04958239CT.gov A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT05175235CT.gov Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | — | Unknown | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT05144698CT.gov RAPA-201 Therapy of Solid Tumors | — | Recruiting | — | — | — |
NCT04541108CT.gov Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | — | Active Not Recruiting | — | — | — |
NCT04840394CT.gov Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04937153CT.gov GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT04866485CT.gov A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody | — | Unknown | — | — | — |
NCT04659629CT.gov NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | — | Completed | — | — | — |
NCT04717375CT.gov Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04720976CT.gov JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05097781CT.gov Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | — | Unknown | — | — | — |
NCT04729348CT.gov Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | — | Terminated | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04571632CT.gov Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | — | Unknown | — | — | — |
NCT04370587CT.gov A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04420884CT.gov A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04443088CT.gov An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04301011CT.gov Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT04344795CT.gov Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04157517CT.gov A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04198766CT.gov Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | — | Active Not Recruiting | — | — | — |
NCT04123366CT.gov Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | — | Active Not Recruiting | — | — | — |
NCT04099277CT.gov A Study of LY3435151 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT03954067CT.gov A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03948763CT.gov A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | — | Terminated | — | — | — |
NCT03918278CT.gov A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | — | Completed | — | — | — |
NCT03829254CT.gov A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | — | Recruiting | — | — | — |
NCT03917381CT.gov GEN1046 Safety Trial in Patients With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03934814CT.gov Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | — | Completed | — | — | — |
NCT03884556CT.gov TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | — | Completed | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03894540CT.gov Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT03832569CT.gov Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03834948CT.gov AO-176 in Multiple Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03815630CT.gov A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors | — | Unknown | — | — | — |
NCT03637803CT.gov Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | — | Terminated | — | — | — |
NCT03709706CT.gov Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab | — | Terminated | — | — | — |
NCT04386967CT.gov OH2 Injection in Solid Tumors | — | Recruiting | — | — | — |
NCT03588039CT.gov Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03815682CT.gov RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | — | Terminated | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03486873CT.gov Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | — | Recruiting | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03564691CT.gov Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | — | Completed | — | — | — |
NCT03416335CT.gov A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | — | Terminated | — | — | — |
NCT03530397CT.gov A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03473925CT.gov Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | — | Completed | — | — | — |
NCT03447314CT.gov Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT03428802CT.gov Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | — | Active Not Recruiting | — | — | — |
NCT03361228CT.gov A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03396445CT.gov Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | — | Completed | — | — | — |
NCT03486301CT.gov BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | — | Completed | — | — | — |
NCT02834052CT.gov Pembrolizumab + Poly-ICLC in MRP Colon Cancer | — | Completed | — | — | — |
NCT03364049CT.gov Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | — | Completed | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03308942CT.gov Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | — | Completed | — | — | — |
NCT03249792CT.gov Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | — | Terminated | — | — | — |
NCT03168438CT.gov Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | — | Terminated | — | — | — |
NCT03313778CT.gov Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02587962CT.gov Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT03099161CT.gov Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | — | Terminated | — | — | — |
NCT03085914CT.gov A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | — | Completed | — | — | — |
NCT02987166CT.gov HDCRT Plus Pembrolizumab in Advanced Malignancies | — | Completed | — | — | — |
NCT02959437CT.gov Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | — | Terminated | — | — | — |
NCT03013218CT.gov A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | — | Completed | — | — | — |
NCT03010176CT.gov Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | — | Completed | — | — | — |
NCT02972034CT.gov Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | — | Terminated | — | — | — |
NCT03006887CT.gov Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT02964013CT.gov Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) | — | Completed | — | — | — |
NCT03360630CT.gov Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC | — | Completed | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
NCT02909452CT.gov Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02903914CT.gov Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03190811CT.gov Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02909348CT.gov Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab | — | Completed | — | — | — |
NCT02783300CT.gov An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT02862457CT.gov Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | — | Completed | — | — | — |
NCT02721732CT.gov Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | — | Active Not Recruiting | — | — | — |
NCT02723955CT.gov Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02720068CT.gov Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | — | Completed | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02635672CT.gov Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT02546531CT.gov Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT02675946CT.gov CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | — | Unknown | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02628574CT.gov Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | — | Completed | — | — | — |
NCT02608385CT.gov Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02521844CT.gov A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | — | Active Not Recruiting | — | — | — |
NCT02528357CT.gov GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) | — | Completed | — | — | — |
NCT02501096CT.gov A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT02332668CT.gov A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | — | Recruiting | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02132754CT.gov Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | — | Completed | — | — | — |
NCT02130466CT.gov A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | — | Completed | — | — | — |
NCT02054806CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01848834CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | — | Completed | — | — | — |
NCT01840579CT.gov Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | — | Completed | — | — | — |
NCT01346358CT.gov A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Mirati Therapeutics Inc. | P3 | B · 58 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →